Health Trials

About this trial

The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.

Eligibility criteria

Qualifiers

Diffuse pleural mesothelioma (DPM)

Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.

PD-L1 CPS ≥1 (using clone 73-10, DAKO)

HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio <2 and average HER2 copy number <6.0 signals/cell

Disqualifiers

Prior treatment with PRMT5i or MAT2Ai

Symptomatic CNS metastases

Patients with treated brain metastases are eligible if follow up brain imaging after CNS directed therapy shows no evidence of progression and the patient is on a stable dose of corticosteroids

Received palliative radiation therapy within 3 days prior to initiation of study treatment or definitive SRS including CNS SRS within 14 days prior to initiation of study treatment

Trial design

Treatments tested in this trial

  • BMS-986504
  • Ipilimumab
  • Nivolumab
  • 5-FU
  • Leucovorin
  • Oxaliplatin
  • Gemcitabine
  • Platinum

Treatment groups

60 Participants
are divided into 3 treatment groups

Locations

7
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)07920, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)11725, CommackNew York, United States

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Bristol-Myers Squibb

Collaborator

Source ClinicalTrials.gov